Inspired by nature: Fundamentals in nanotechnology design to overcome biological barriers

Therapeutic Delivery

Volumn 4, Issue 1, 2013, Pages 27-43

  Avila Olias, Milagros ^a   Pegoraro, Carla ^a   Battaglia, Giuseppe ^a   Canton, Irene ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ARGINYLGLYCYLASPARTIC ACID; CELL PENETRATING PEPTIDE; CHITOSAN; DNA FRAGMENT; GADOTERIC ACID; IMMUNOLIPOSOME; IMMUNOLOGICAL ADJUVANT; LIPID; LIPOSOME; MACROGOL; NANOCARRIER; NANOMATERIAL; NANOPARTICLE; NUCLEIC ACID; OLIGONUCLEOTIDE; OPSONIN; PEGINTERFERON ALPHA; PEPTIDE; POLY(METHYL METHACRYLATE); POLY(PROPYLACRILIC ACID); POLYETHYLENEIMINE; POLYMER; POLYMERSOME; POVIDONE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE;

BIOLOGICAL BARRIER; BIOLOGY; BIOMEDICINE; BLOOD BRAIN BARRIER; CELL MEMBRANE; CELL NUCLEUS MEMBRANE; CELL SHAPE; CELL SIZE; CELL SURFACE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; ENDOCYTOSIS; ENDOSOME; ERYTHROCYTE MEMBRANE; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; IMMUNE RESPONSE; IMMUNOMODULATION; MICELLE; MICELLIZATION; NANOPHARMACEUTICS; NANOTECHNOLOGY; NEOPLASM; NONHUMAN; OPSONIZATION; PRIORITY JOURNAL; REVIEW; VIRAL GENE DELIVERY SYSTEM;

EID: 84871580899     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.12.126     Document Type: Review

References (145)

1. Sharma P, Garg S. Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs. Adv. Drug Deliver. Rev. 62(4-5), 491-502 (2010).
2. Anand P, Nair HB, Sung BK et al. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem. Pharmacol. 79(3), 330-338 (2010).
3. Almeida JP, Chen AL, Foster A, Drezek R. In vivo biodistribution of nanoparticles. Nanomedicine (Lond. ) 6(5), 815-835 (2011).
4. Elsaesser A, Howard CV. Toxicology of nanoparticles. Adv. Drug Deliver. Rev. 64(2), 129-137 (2012).
5. Dobrovolskaia MA, Aggarwal P, Hall JB, Mcneil SE. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol. Pharm. 5(4), 487-495 (2008).
6. Nasir A. Nanotechnology in vaccine development: a step forward. J. Invest. Dermatol. 129(5), 1055-1059 (2009).
7. Zolnik BS, Gonzalez-Fernandez A, Sadrieh N, Dobrovolskaia MA. Minireview: nanoparticles and the immune system. Endocrinology 151(2), 458-465 (2010).
8. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J. Leukocyte Biol. 81(1), 1-5 (2007).
9. Newton K, Dixit VM. Signaling in innate immunity and inflammation. Cold Spring Harb. Perspect. Biol. 4(3), (2012).
10. Seong SY, Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat. Rev. Immunol. 4(6), 469-478 (2004).
11. Moon JJ, Suh H, Bershteyn A et al. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat. Mater. 10(3), 243-251 (2011).
12. Esmaeili F, Ghahremani MH, Esmaeili B, Khoshayand MR, Atyabi F, Dinarvand R. PLGA nanoparticles of different surface properties: preparation and evaluation of their body distribution. Int. J. Pharm. 349(1-2), 249-255 (2008).
13. Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307(1), 93-102 (2006).
14. Tromsdorf UI, Bruns OT, Salmen SC, Beisiegel U, Weller H. A highly effective, nontoxic T1 MR contrast agent based on ultrasmall PEGylated iron oxide nanoparticles. Nano Lett. 9(12), 4434-4440 (2009).
15. Yang ST, Fernando KA, Liu JH et al. Covalently PEGylated carbon nanotubes with stealth character in vivo. Small 4(7), 940-944 (2008).
16. Prencipe G, Tabakman SM, Welsher K et al. PEG branched polymer for functionalization of nanomaterials with ultralong blood circulation. J. Am. Chem. Soc. 131(13), 4783-4787 (2009).
17. Dos Santos N, Allen C, Doppen AM et al. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. Biochim. Biophys. Acta 1768(6), 1367-1377 (2007).
18. Mckeating JA, Griffiths PD, Grundy JE. Cytomegalovirus in urine specimens has host beta 2 microglobulin bound to the viral envelope: a mechanism of evading the host immune response? J. Gen. Virol. 68(Pt 3), 785-792 (1987).
19. Manns MP, Mchutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358(9286), 958-965 (2001).
20. Rajender Reddy K, Modi MW, Pedder S. Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C. Adv. Drug Deliver. Rev. 54(4), 571-586 (2002).
21. Couvreur P, Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm. Res. 23(7), 1417-1450 (2006).
22. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomedicine 1(3), 297-315 (2006).
23. Allen TM, Hansen C, Martin F, Redemann C, Yauyoung A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta 1066(1), 29-36 (1991).
24. Zalipsky S, Brandeis E, Newman MS, Woodle MC. Long circulating, cationic liposomes containing amino-peg-phosphatidylethanolamine. FEBS Lett. 353(1), 71-74 (1994).
25. Leal C, Rognvaldsson S, Fossheim S, Nilssen EA, Topgaard D. Dynamic and structural aspects of PEGylated liposomes monitored by NMR. J. Colloid Interf. Sci. 325(2), 485-493 (2008).
26. Mishra S, Webster P, Davis ME. PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur. J. Cell Biol. 83(3), 97-111 (2004).
27. Kumagai M, Shimoda S, Wakabayashi R et al. Effective transgene expression without toxicity by intraperitoneal administration of PEG-detachable polyplex micelles in mice with peritoneal dissemination. J. Control. Release 160(3), 542-551 (2012).
28. Moghimi SM. Recent developments in polymeric nanoparticle engineering and their applications in experimental and clinical oncology. Anticancer Agents Med. Chem. 6(6), 553-561 (2006).
29. Knop K, Hoogenboom R, Fischer D, Schubert US. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew. Chem. Int. Ed. Engl. 49(36), 6288-6308 (2010).
30. Photos PJ, Bacakova L, Discher B, Bates FS, Discher DE. Polymer vesicles in vivo: correlations with PEG molecular weight. J. Control. Release 90(3), 323-334 (2003).
31. Teichroeb JH, Forrest JA, Jones LW, Chan J, Dalton K. Quartz crystal microbalance study of protein adsorption kinetics on poly(2-hydroxyethyl methacrylate). J. Colloid Interface Sci. 325(1), 157-164 (2008).
32. Huang J, Bu L, Xie J et al. Effects of nanoparticle size on cellular uptake and liver MRI with polyvinylpyrrolidone-coated iron oxide nanoparticles. ACS Nano 4(12), 7151-7160 (2010).
33. Konradi R, Pidhatika B, Muhlebach A, Textor M. Poly-2-methyl-2-oxazoline: a peptide-like polymer for protein-repellent surfaces. Langmuir 24(3), 613-616 (2008).
34. Walkey CD, Olsen JB, Guo HB, Emili A, Chan WCW. Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. J. Am. Chem. Soc. 134(4), 2139-2147 (2012).
35. Muzykantov VR. Drug delivery by red blood cells: vascular carriers designed by mother nature. Expert Opin. Drug Deliv. 7(4), 403-427 (2010).
36. Merkel TJ, Jones SW, Herlihy KP et al. Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles. Proc. Natl Acad. Sci. USA 108(2), 586-591 (2011).
37. Tsai RK, Rodriguez PL, Discher DE. Self inhibition of phagocytosis: the affinity of 'marker of self ' CD47 for SIRPalpha dictates potency of inhibition but only at low expression levels. Blood Cells Mol. Dis. 45(1), 67-74 (2010).
38. Hu CM, Zhang L, Aryal S, Cheung C, Fang RH. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl Acad. Sci. USA 108(27), 10980-10985 (2011).
39. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 284(5418), 1318-1322 (1999).
40. Jokiranta TS. C3b and factor H. Key components of the complement system. Expert Rev. Clin. Immunol. 2(5), 775-786 (2006).
41. Hellwage J, Meri T, Heikkila T et al. The complement regulator factor H binds to the surface protein OspE of Borrelia burgdorferi. J. Biol. Chem. 276(11), 8427-8435 (2001).
42. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53(2), 283-318 (2001).
43. Pham CT, Mitchell LM, Huang JL et al. Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces. J. Biol. Chem. 286(1), 123-130 (2011).
44. Thomas SN, Van Der Vlies AJ, O'neil CP et al. Engineering complement activation on polypropylene sulfide vaccine nanoparticles. Biomaterials 32(8), 2194-2203 (2011).
45. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 5(4), 505-515 (2008).
46. Canton I, Battaglia G. Endocytosis at the nanoscale. Chem. Soc. Rev. 41(7), 2718-2739 (2012).
47. Fang C, Shi B, Pei YY, Hong MH, Wu J, Chen HZ. In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size. Eur. J. Pharm. Sci. 27(1), 27-36 (2006).
48. Qaddoumi MG, Ueda H, Yang J, Davda J, Labhasetwar V, Lee VH. The characteristics and mechanisms of uptake of PLGA nanoparticles in rabbit conjunctival epithelial cell layers. Pharm. Res. 21(4), 641-648 (2004).
49. Massignani M, Lopresti C, Blanazs A et al. Controlling cellular uptake by surface chemistry, size, and surface topology at the nanoscale. Small 5(21), 2424-2432 (2009).
50. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin-and caveolae-mediated endocytosis. Biochem. J. 377, 159-169 (2004).
51. Zuhorn IS, Kalicharan R, Hoekstra D. Lipoplex-mediated transfection of mammalian cells occurs through the cholesterol-dependent clathrin-mediated pathway of endocytosis. J. Biol. Chem. 277(20), 18021-18028 (2002).
52. Lai SK, Hida K, Man ST et al. Privileged delivery of polymer nanoparticles to the perinuclear region of live cells via a non-clathrin, non-degradative pathway. Biomaterials 28(18), 2876-2884 (2007).
53. Muro S, Garnacho C, Champion JA et al. Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. Mol. Ther. 16(8), 1450-1458 (2008).
54. Roiter Y, Ornatska M, Rammohan AR, Balakrishnan J, Heine DR, Minko S. Interaction of lipid membrane with nanostructured surfaces. Langmuir 25(11), 6287-6299 (2009).
55. Geng Y, Dalhaimer P, Cai S et al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat. Nanotechnol. 2(4), 249-255 (2007).
56. Xu ZP, Niebert M, Porazik K et al. Subcellular compartment targeting of layered double hydroxide nanoparticles. J. Control. Release 130(1), 86-94 (2008).
57. Harush-Frenkel O, Debotton N, Benita S, Altschuler Y. Targeting of nanoparticles to the clathrin-mediated endocytic pathway. Biochem. Biophys. Res. Commun. 353(1), 26-32 (2007).
58. Mao SR, Sun W, Kissel T. Chitosan-based formulations for delivery of DNA and siRNA. Adv. Drug Deliver. Rev. 62(1), 12-27 (2010).
59. Xia TA, Kovochich M, Liong M et al. polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs. ACS Nano 3(10), 3273-3286 (2009).
60. Kim SH, Jeong JH, Chun KW, Park TG. Target-specific cellular uptake of PLGA nanoparticles coated with poly(l-lysine)-poly(ethylene glycol)-folate conjugate. Langmuir 21(19), 8852-8857 (2005).
61. Safinya CR. Structures of lipid-DNA complexes: supramolecular assembly and gene delivery. Curr. Opin. Struc. Biol. 11(4), 440-448 (2001).
62. Zhang SB, Zhao B, Jiang HM, Wang B, Ma BC. Cationic lipids and polymers mediated vectors for delivery of siRNA. J. Control. Release 123(1), 1-10 (2007).
63. De Jong WH, Borm PJA. Drug delivery and nanoparticles: applications and hazards. Int. J. Nanomed. 3(2), 133-149 (2008).
64. Cho KJ, Wang X, Nie SM, Chen Z, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res. 14(5), 1310-1316 (2008).
65. Li GP, Li D, Zhang LX, Zhai JF, Wang EK. One-step synthesis of folic acid protected gold nanoparticles and their receptor-mediated intracellular uptake. Chem. Eur. J. 15(38), 9868-9873 (2009).
66. Aktas Y, Yemisci M, Andrieux K et al. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjug. Chem. 16(6), 1503-1511 (2005).
67. Gao J, Kou G, Chen HW et al. Treatment of hepatocellular carcinoma in mice with PE38KDEL type I mutant-loaded poly(lactic-co-glycolic acid) nanoparticles conjugated with humanized SM5-1 F(ab́) fragments. Mol. Cancer Ther. 7(10), 3399-3407 (2008).
68. Kirpotin DB, Drummond DC, Shao Y et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 66(13), 6732-6740 (2006).
69. Cheng WWK, Allen TM. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab́ fragments and single chain Fv. J. Control. Release 126(1), 50-58 (2008).
70. Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur. J. Pharm. Biopharm. 71(3), 409-419 (2009).
71. Almutairi A, Rossin R, Shokeen M et al. Biodegradable dendritic positron-emitting nanoprobes for the noninvasive imaging of angiogenesis. Proc. Natl Acad. Sci. USA 106(3), 685-690 (2009).
72. Schmieder AH, Caruthers SD, Zhang H et al. Three-dimensional MR mapping of angiogenesis with alpha(5)beta(1)(alpha(v) beta(3))-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model. FASEB J. 22(12), 4179-4189 (2008).
73. Sugahara KN, Teesalu T, Karmali PP et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328(5981), 1031-1035 (2010).
74. Silhol M, Tyagi M, Giacca M, Lebleu B, Vives E. Different mechanisms for cellular internalization of the HIV-1 Tat-derived cell penetrating peptide and recombinant proteins fused to Tat. Eur. J. Biochem. 269(2), 494-501 (2002).
75. Berry CC. Intracellular delivery of nanoparticles via the HIV-1 tat peptide. Nanomedicine (Lond. ) 3(3), 357-365 (2008).
76. Mishra A, Lai GH, Schmidt NW et al. Translocation of HIV TAT peptide and analogues induced by multiplexed membrane and cytoskeletal interactions. Proc. Natl Acad. Sci. USA 108(41), 16883-16888 (2011).
77. Santra S, Yang H, Dutta D et al. TAT conjugated, FITC doped silica nanoparticles for bioimaging applications. Chem. Commun. (24), 2810-2811 (2004).
78. Mudhakir D, Harashima H. Learning from the viral journey: how to enter cells and how to overcome intracellular barriers to reach the nucleus. AAPS J. 11(1), 65-77 (2009).
79. Anderson RG. The caveolae membrane system. Annu. Rev. Biochem. 67, 199-225 (1998).
80. Middleton J, Neil S, Wintle J et al. Transcytosis and surface presentation of IL-8 by venular endothelial cells. Cell 91(3), 385-395 (1997).
81. Hansen GH, Niels-Christiansen LL, Immerdal L, Hunziker W, Kenny AJ, Danielsen EM. Transcytosis of immunoglobulin A in the mouse enterocyte occurs through glycolipid raft-and Rab17-containing compartments. Gastroenterology 116(3), 610-622 (1999).
82. Meier O, Greber UF. Adenovirus endocytosis. J. Gene Med. 5(6), 451-462 (2003).
83. Kwon EJ, Bergen JM, Park IK, Pun SH. Peptide-modified vectors for nucleic acid delivery to neurons. J. Control. Release 132(3), 230-235 (2008).
84. Hatakeyama H, Ito E, Akita H et al. A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo. J. Control. Release 139(2), 127-132 (2009).
85. Semple SC, Akinc A, Chen JX et al. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 28(2), 172-176 (2010).
86. Foster S, Duvall CL, Crownover EF, Hoffman AS, Stayton PS. Intracellular delivery of a protein antigen with an endosomal-releasing polymer enhances CD8 T-cell production and prophylactic vaccine efficacy. Bioconjug. Chem. 21(12), 2205-2212 (2010).
87. Xiao PJ, Samulski RJ. Cytoplasmic trafficking, endosomal escape, and perinuclear accumulation of adeno-associated virus type 2 particles are facilitated by microtubule network. J. Virol. 86(19), 10462-10473 (2012).
88. Liebl D, Difato F, Hornikova L, Mannova P, Stokrova J, Forstova J. Mouse polyomavirus enters early endosomes, requires their acidic pH for productive infection, and meets transferrin cargo in Rab11-positive endosomes. J. Virol. 80(9), 4610-4622 (2006).
89. Qian M, Cai D, Verhey KJ, Tsai B. A lipid receptor sorts polyomavirus from the endolysosome to the endoplasmic reticulum to cause infection. PLoS Pathog. 5(6), e1000465 (2009).
90. Engel S, Heger T, Mancini R et al. Role of endosomes in simian virus 40 entry and infection. J. Virol. 85(9), 4198-4211 (2011).
91. Agosto MA, Ivanovic T, Nibert ML. Mammalian reovirus, a nonfusogenic nonenveloped virus, forms size-selective pores in a model membrane. Proc. Natl Acad. Sci. USA 103(44), 16496-16501 (2006).
92. Duncan R, Izzo L. Dendrimer biocompatibility and toxicity. Adv. Drug Deliver. Rev. 57(15), 2215-2237 (2005).
93. Ahmed F, Discher DE. Self-porating polymersomes of PEG-PLA and PEG-PCL: hydrolysis-triggered controlled release vesicles. J. Control. Release 96(1), 37-53 (2004).
94. Cerritelli S, Velluto D, Hubbell JA. PEG-SS-PPS: reduction-sensitive disulfide block copolymer vesicles for intracellular drug delivery. Biomacromolecules 8(6), 1966-1972 (2007).
95. Chen W, Meng FH, Cheng R, Zhong ZY. pH-sensitive degradable polymersomes for triggered release of anticancer drugs: a comparative study with micelles. J. Control. Release 142(1), 40-46 (2010).
96. Lomas H, Massignani M, Abdullah KA et al. Non-cytotoxic polymer vesicles for rapid and efficient intracellular delivery. Faraday Discuss. 139, 143-159 (2008).
97. Hearnden V, Lomas H, Macneil S et al. Diffusion studies of nanometer polymersomes across tissue engineered human oral mucosa. Pharm. Res. Disord. 26(7), 1718-1728 (2009).
98. Buschow SI, Nolte-T Hoen EN, Van Niel G et al. MHC II in dendritic cells is targeted to lysosomes or T cell-induced exosomes via distinct multivesicular body pathways. Traffic 10(10), 1528-1542 (2009).
99. Van Den Boorn JG, Schlee M, Coch C, Hartmann G. siRNA delivery with exosome nanoparticles. Nat. Biotechnol. 29(4), 325-326 (2011).
100. Perez-Martinez FC, Guerra J, Posadas I, Cena V. Barriers to non-viral vector-mediated gene delivery in the nervous system. Pharm. Res. Disord. 28(8), 1843-1858 (2011).
101. Brus C, Petersen H, Aigner A, Czubayko F, Kissel T. Efficiency of polyethylenimines and polyethylenimine-graft-poly (ethylene glycol) block copolymers to protect oligonucleotides against enzymatic degradation. Eur. J. Pharm. Biopharm. 57(3), 427-430 (2004).
102. Godbey WT, Barry MA, Saggau P, Wu KK, Mikos AG. Poly(ethylenimine)- mediated transfection: a new paradigm for gene delivery. J. Biomed. Mater. Res. 51(3), 321-328 (2000).
103. Yaroslavov AA, Sukhishvili SA, Obolsky OL, Yaroslavova EG, Kabanov AV, Kabanov VA. DNA affinity to biological membranes is enhanced due to complexation with hydrophobized polycation. FEBS Lett. 384(2), 177-180 (1996).
104. Luo D, Saltzman WM. Enhancement of transfection by physical concentration of DNA at the cell surface. Nat. Biotechnol. 18(8), 893-895 (2000).
105. Ciolina C, Byk G, Blanche F, Thuillier V, Scherman D, Wils P. Coupling of nuclear localization signals to plasmid DNA and specific interaction of the conjugates with importin alpha. Bioconjug. Chem. 10(1), 49-55 (1999).
106. Opanasopit P, Rojanarata T, Apirakaramwong A, Ngawhirunpat T, Ruktanonchai U. Nuclear localization signal peptides enhance transfection efficiency of chitosan/DNA complexes. Int. J. Pharm. 382(1-2), 291-295 (2009).
107. van der Aa Ma, Koning GA, d'Oliveira C et al. An NLS peptide covalently linked to linear DNA does not enhance transfection efficiency of cationic polymer based gene delivery systems. J. Gene Med. 7(2), 208-217 (2005).
108. Tanimoto M, Kamiya H, Minakawa N, Matsuda A, Harashima H. No enhancement of nuclear entry by direct conjugation of a nuclear localization signal peptide to linearized DNA. Bioconjug. Chem. 14(6), 1197-1202 (2003).
109. Keller M, Tagawa T, Preuss M, Miller AD. Biophysical characterization of the DNA binding and condensing properties of adenoviral core peptide mu. Biochemistry 41(2), 652-659 (2002).
110. Akita H, Tanimoto M, Masuda T et al. Evaluation of the nuclear delivery and intra-nuclear transcription of plasmid DNA condensed with mu (mu) and NLS-mu by cytoplasmic and nuclear microinjection: a comparative study with poly-l-lysine. J. Gene Med. 8(2), 198-206 (2006).
111. Holmes AR, Dohrman AF, Ellison AR, Goncz KK, Gruenert DC. Intracellular compartmentalization of DNA fragments in cultured airway epithelial cells mediated by cationic lipids. Pharm. Res. Disord. 16(7), 1020-1025 (1999).
112. Boussif O, Lezoualch F, Zanta MA et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo polyethylenimine. Proc. Natl Acad. Sci. USA 92(16), 7297-7301 (1995).
113. Nguyen DN, Mahon KP, Chikh G et al. Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery. Proc. Natl Acad. Sci. USA 109(14), E797-E803 (2012).
114. Godbey WT, Wu KK, Mikos AG. Size matters: molecular weight affects the efficiency of poly(ethylenimine) as a gene delivery vehicle. J. Biomed. Mater. Res. 45(3), 268-275 (1999).
115. Von Harpe A, Petersen H, Li Y, Kissel T. Characterization of commercially available and synthesized polyethylenimines for gene delivery. J. Control. Release 69(2), 309-322 (2000).
116. Zugates GT, Peng W, Zumbuehl A et al. Rapid optimization of gene delivery by parallel end-modification of poly(beta-amino ester)s. Mol. Ther. 15(7), 1306-1312 (2007).
117. Peng Q, Zhong Z, Zhuo R. Disulfide cross-linked polyethylenimines (PEI) prepared via thiolation of low molecular weight PEI as highly efficient gene vectors. Bioconjug. Chem. 19(2), 499-506 (2008).
118. Abdallah B, Hassan A, Benoist C, Goula D, Behr JP, Demeneix BA. A powerful nonviral vector for in vivo gene transfer into the adult mammalian brain: polyethylenimine. Hum. Gene Ther. 7(16), 1947-1954 (1996).
119. Namgung R, Kim J, Singha K, Kim CH, Kim WJ. Synergistic effect of low cytotoxic linear polyethylenimine and multiarm polyethylene glycol: study of physicochemical properties and in vitro gene transfection. Mol. Pharm. 6(6), 1826-1835 (2009).
120. Boletta A, Benigni A, Lutz J, Remuzzi G, Soria MR, Monaco L. Nonviral gene delivery to the rat kidney with polyethylenimine. Hum. Gene Ther. 8(10), 1243-1251 (1997).
121. Wiseman JW, Goddard CA, Mclelland D, Colledge WH. A comparison of linear and branched polyethylenimine (PEI) with DCChol/DOPE liposomes for gene delivery to epithelial cells in vitro and in vivo. Gene Ther. 10(19), 1654-1662 (2003).
122. Lin C, Blaauboer CJ, Timoneda MM et al. Bioreducible poly(amido amine)s with oligoamine side chains: synthesis, characterization, and structural effects on gene delivery. J. Control. Release 126(2), 166-174 (2008).
123. Deng R, Yue Y, Jin F et al. Revisit the complexation of PEI and DNA-how to make low cytotoxic and highly efficient PEI gene transfection non-viral vectors with a controllable chain length and structure? J. Control. Release 140(1), 40-46 (2009).
124. Shahin V, Albermann L, Schillers H et al. Steroids dilate nuclear pores imaged with atomic force microscopy. J. Cell Physiol. 202(2), 591-601 (2005).
125. Ma K, Hu MX, Qi Y et al. Structure-transfection activity relationships with glucocorticoid-polyethylenimine conjugate nuclear gene delivery systems. Biomaterials 30(22), 3780-3789 (2009).
126. Goldmann EE. Vitalfärbung am Zentralnervensystem. Abh. Preuss Akad. Wiss. Phys. Math. 1, 1-60 (1913).
127. Elrich P. Das sauerstoff-bedürfnis des organismus. In: Eine Farbenanalytiche Studie. Hirschwald, Berlin, Germany, 1-167 (1885).
128. Stern L. Le liquide céphalo rachidien au point de vue de ses rapports avec la circulation sanguine et avec les éléments de l'axe cérébro-spinal. Schweiz. Arch. Neurol. Psychiatr. 8, 215-232 (1921).
129. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol. Rev. 57(2), 173-185 (2005).
130. De Boer AG, Gaillard PJ. Drug targeting to the brain. Annu. Rev. Pharmacol. Toxicol. 47, 323-355 (2007).
131. Yan Q, Matheson C, Sun J, Radeke MJ, Feinstein SC, Miller JA. Distribution of intracerebral ventricularly administered neurotrophins in rat brain and its correlation with TRK receptor expression. Exp. Neurol. 127(1), 23-36 (1994).
132. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29(4), 341-345 (2011).
133. Lafon M. Rabies virus receptors. J. Neurovirol. 11(1), 82-87 (2005).
134. Kumar P, Wu HQ, Mcbride JL et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 448(7149), 39-43 (2007).
135. Park IK, Lasiene J, Chou SH, Horner PJ, Pun SH. Neuron-specific delivery of nucleic acids mediated by Tet(1)-modified poly(ethylenimine). J. Gene Med. 9(8), 691-702 (2007).
136. Skjorringe T, Gjetting T, Jensen TG. A modified protocol for efficient DNA encapsulation into PEGylated immunoliposomes (PILs). J. Control. Release 139(2), 140-145 (2009).
137. Chang J, Jallouli Y, Kroubi M et al. Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood-brain barrier. Int. J. Pharm. 379(2), 285-292 (2009).
138. Madhankumar AB, Slagle-Webb B, Wang X et al. Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor model. Mol. Cancer Ther. 8(3), 648-654 (2009).
139. Reddy JA, Allagadda VM, Leamon CP. Targeting therapeutic and imaging agents to folate receptor positive tumors. Curr. Pharm. Biotechnol. 6(2), 131-150 (2005).
140. Beduneau A, Saulnier P, Benoit JP. Active targeting of brain tumors using nanocarriers. Biomaterials 28(33), 4947-4967 (2007).
141. Huwyler J, Wu D, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl Acad. Sci. USA 93(24), 14164-14169 (1996).
142. Zhang Y, Calon F, Zhu C, Boado RJ, Pardridge WM. Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum. Gene Ther. 14(1), 1-12 (2003).
143. Schnyder A, Krahenbuhl S, Drewe J, Huwyler J. Targeting of daunomycin using biotinylated immunoliposomes: pharmacokinetics, tissue distribution and in vitro pharmacological effects. J. Drug Target 13(5), 325-335 (2005).
144. Gupta B, Torchilin VP. Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice. Cancer Immunol. Immunother. 56(8), 1215-1223 (2007).
145. Du J, Lu WL, Ying X et al. Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals. Mol. Pharm. 6(3), 905-917 (2009).